ID   HMC-1-8
AC   CVCL_2949
SY   HMC18
DR   CLO; CLO_0037257
DR   ArrayExpress; E-MTAB-2770
DR   BioGRID_ORCS_Cell_line; 656
DR   BioSample; SAMN03470817
DR   BioSample; SAMN10987868
DR   cancercelllines; CVCL_2949
DR   Cell_Model_Passport; SIDM01622
DR   DepMap; ACH-000721
DR   IARC_TP53; 28374
DR   JCRB; JCRB0166
DR   JCRB; FDSC0048
DR   LiGeA; CCLE_562
DR   PharmacoDB; HMC18_552_2019
DR   Progenetix; CVCL_2949
DR   SLKBase; 3552
DR   Wikidata; Q54889908
RX   DOI=10.15114/tr.22.27;
RX   PubMed=3488124;
RX   PubMed=26589293;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: 26 hours (DOI=10.15114/tr.22.27).
CC   HLA typing: A*24:02,31:01; B*07:13,35:08; C*01:02,07:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Argfs*18 (c.455delC); ClinVar=VCV000634779; Zygosity=Unspecified (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=83.08%; East Asian, South=16.92%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; FDSC0048; true.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): JCRB
ST   Amelogenin: X
ST   CSF1PO: 7,12
ST   D13S317: 8,10
ST   D16S539: 9,12
ST   D5S818: 9,10
ST   D7S820: 11
ST   TH01: 7,9
ST   TPOX: 8,12
ST   vWA: 16,17
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_H204 ! TcHMC-1
SX   Female
AG   35Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 24
//
RX   DOI=10.15114/tr.22.27;
RA   Sato T., Sato N., Takahashi S., Okubo M., Yagihashi A., Okazaki A.,
RA   Okazaki Y., Toda K.;
RT   "Characterization of two new cancer cell lines derived from human
RT   breast tumors.";
RL   Tumor Res. 22:27-39(1987).
//
RX   PubMed=3488124;
RA   Sato T., Sato N., Takahashi S., Koshiba H., Kikuchi K.;
RT   "Specific cytotoxicity of a long-term cultured T-cell clone on human
RT   autologous mammary cancer cells.";
RL   Cancer Res. 46:4384-4389(1986).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//